NPPA fixes prices of 22 drug formulations

The national drug pricing regulator NPPA has fixed the retail and ceiling prices of 22 formulations used for treatment of various ailments including HIV, bacterial infections and cardiac conditions among others.

While National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 20 formulations, it has also capped the ceiling prices of two formulations, a notification on the regulator’s website said.

The prices have been fixed/revised under the Drug (Prices Control) Order, 2013, it added.

The regulator has fixed ceiling prices of Co-trimoxazole (Sulphamethoxazole(A) and Trimethoprim(B) tablets used for treating a variety of bacterial infections and oral rehydration salt (ORS).

It has also fixed the retail prices of drugs manufactured and marketed by various firms such as Omeprazole Domperidone capsule used for treatment of acidity and gastroesophageal reflux disease, Clotrimazole Beclomethasone cream used for treating variety of inflamed fungal skin infections.

The regulator has also fixed the retail price of Rosuvastatin Clopidogrel tablet used to lower cholesterol level and triglycerides and Tenofovir Disoproxil Fumarate Lamividine Efavirenz tablet used in treatment of HIV, among others.

The NPPA is mandated to fix/revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.

It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.

The regulator implements and enforces the provisions of the Drugs (Prices Control) Order.

It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.

  • Related Posts

    HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

    In a landmark ruling that will have far-reaching implications for the pharmaceutical sector, the High Court of Himachal Pradesh has quashed three criminal complaints filed by the Central Drugs Standard…

    Eli Lilly launches cancer drug Tanstrive in India

    New Delhi: Eli Lilly and Company India on Thursday announced the launch of its cancer treatment drug Tanstrive in India. The launch follows marketing authorisation from the Central Drugs Standard Control Organisation…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

    HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

    Eli Lilly launches cancer drug Tanstrive in India

    Eli Lilly launches cancer drug Tanstrive in India

    Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

    Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

    Centre eases BIS quality compliance with new risk-based framework for manufacturers

    Centre eases BIS quality compliance with new risk-based framework for manufacturers

    SS Innovations International aces Race beating Global Giants in Surgical Robotics

    SS Innovations International aces Race beating Global Giants in Surgical Robotics

    ‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

    ‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility